LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.39 -0.45

Buy Sell

Overview

Share price change

24h

Current

Min

4.31

Max

4.51

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+216.74% upside

Market Stats
By TradingEconomics
Market Cap	-14M 240M
Previous open	4.84
Previous close	4.39

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 gru 2025, 23:58 UTC

Acquisitions, Mergers, Takeovers

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 gru 2025, 23:56 UTC

Earnings

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 gru 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 gru 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 gru 2025, 21:50 UTC

Earnings

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 gru 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

11 gru 2025, 23:44 UTC

Market Talk

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 gru 2025, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 gru 2025, 23:31 UTC

Earnings

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 gru 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 gru 2025, 22:35 UTC

Earnings

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 gru 2025, 22:30 UTC

Earnings

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 gru 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 gru 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 gru 2025, 22:05 UTC

Earnings

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 gru 2025, 21:51 UTC

Acquisitions, Mergers, Takeovers

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

11 gru 2025, 21:39 UTC

Earnings

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 gru 2025, 21:39 UTC

Earnings

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 gru 2025, 21:38 UTC

Earnings

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 gru 2025, 21:37 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 gru 2025, 21:37 UTC

Market Talk

Broadcom Sees AI Revenue Doubling -- Market Talk

11 gru 2025, 21:34 UTC

Acquisitions, Mergers, Takeovers

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 gru 2025, 21:28 UTC

Market Talk

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Dexus: Third Party Investors to Contribute Remainder

11 gru 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 gru 2025, 21:25 UTC

Acquisitions, Mergers, Takeovers

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

216.74% upside

12 Months Forecast

Average 14 USD 216.74%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.